Preparation of anti-tumor nanoparticle and its inhibition to peritoneal dissemination of colon cancer

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Tang, Qingchao ^a   Wang, Yihui ^a   Huang, Rui ^a   You, Qi ^a   Wang, Guiyu ^a   Chen, Yinggang ^a   Jiang, Zheng ^a   Liu, Zheng ^a   Yu, Lei ^a   Muhammad, Shan ^a   Wang, Xishan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; NANOPARTICLE; PEGYLATED POLYGLACTIN; POLYGLACTIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CELL VIABILITY; COLON CANCER; COLONY FORMATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG RELEASE; EMULSION; ENCAPSULATION; HCT116 CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MESENTERY; MOUSE; NONHUMAN; NUDE MOUSE; PARTICLE SIZE; PERITONEAL CAVITY; PERITONEUM METASTASIS; SCANNING ELECTRON MICROSCOPY; ANIMAL; CHEMISTRY; COLONIC NEOPLASMS; DRUG DELIVERY SYSTEM; PATHOLOGY; PERITONEAL NEOPLASMS; SECONDARY; TUMOR CELL LINE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG DELIVERY SYSTEMS; FLUOROURACIL; HUMANS; MICE; MICE, NUDE; NANOPARTICLES; PARTICLE SIZE; PERITONEAL NEOPLASMS;

EID: 84902437055     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098455     Document Type: Article

References (26)

1. Jayne DG, Fook S, Loi C, Seow-Choen F (2002) Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89: 1545-1550. (Pubitemid 35404323)
2. Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP (2006) Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 243: 212-222. (Pubitemid 43185440)
3. Gomez-Portilla A, Cendoya I, de Tejada I L, Olabarria I, Magrach L, de Lecea C M, et al. (2005) Principles of the treatment of peritoneal carcinomatosis due to colorectal cancer. Current review and update. Cir Esp 77: 6-17.
4. Yang SH, Lin JK, Lai CR, Chen CC, Li AF, et al. (2004) Risk factors for peritoneal dissemination of colorectal cancer. J Surg Oncol 87: 167-173. (Pubitemid 39167383)
5. Drecoll E, Gaertner FC, Miederer M, Blechert B, Vallon M, et al. (2009) Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells. PLOS ONE 4: e5715.
6. Couvreur P (2013) Nanoparticles in drug delivery: past, present and future. Adv Drug Deliv Rev 65: 21-23.
7. Chaturvedi K, Ganguly K, Nadagouda MN, Aminabhavi TM (2013) Polymeric hydrogels for oral insulin delivery. J Control Release 165: 129-138.
8. Smith MH, Lyon LA (2012) Multifunctional nanogels for siRNA delivery. Acc Chem Res 45: 985-993.
9. Wang AZ, Langer R, Farokhzad OC (2012) Nanoparticle delivery of cancer drugs. Annu Rev Med 63: 185-198.
10. Burke AR, Singh RN, Carroll DL, Wood JC, D'Agostino RB Jr, et al. (2012) The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy. Biomaterials 33: 2961-2970.
11. Li S, Wang A, Jiang W, Guan Z (2008) Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. BMC Cancer 8: 103.
12. Li Q, Zou C, Zou C, Han Z, Xiao H, et al. (2013) MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7. Cancer Lett 335: 168-174.
13. de Cuba EM, Kwakman R, van Egmond M, Bosch LJ, Bonjer HJ, et al. (2012) Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer: future possibilities for personalised treatment by use of biomarkers. Virchows Arch 461: 231-243.
14. Pera M, Gallego R, Montagut C, Martin-Richard M, Iglesias M, et al. (2012) Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. Ann Oncol 23: 664-670.
15. Hasegawa S, Mukai M, Sato S, Ninomiya H, Wakui K, et al. (2006) Long-term survival and tumor 5-FU sensitivity in patients with stage IV colorectal cancer and peritoneal dissemination. Oncol Rep 15: 1185-1190.
16. Chester JD, Dent JT, Wilson G, Ride E, Seymour MT (2000) Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer. Ann Oncol 11: 235-237. (Pubitemid 30148743)
17. Wang Y, Gong C, Yang L, Wu Q, Shi S, et al. (2010) 5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice. BMC Cancer 10: 402.
18. Lin H, Ren H, Wang XS, Tang QC, Tang J, et al. (2008) Preparation of 5-Fluorouracil Loaded Polylactide-co-glycolide-co-methoxy Poly(ethylene glycol) (PLGA-mPEG) Nanoparticles via High Speed Shearing. Chem. Res. Chinese Universities. 24(6), 805-808.
19. Lu H, Li B, Kang Y, Jiang W, Huang Q, et al. (2007) Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting. Cancer Chemother Pharmacol 59: 175-181. (Pubitemid 44885147)
20. Wohlfart S, Khalansky AS, Gelperina S, Maksimenko O, Bernreuther C, et al. (2011) Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers. PLoS One 6: e19121.
21. Lamppa JW, Ackerman ME, Lai JI, Scanlon TC, Griswold KE (2011) Genetically engineered alginate lyase-PEG conjugates exhibit enhanced catalytic function and reduced immunoreactivity. PLoS One 6: e17042.
22. Brigger I, Dubernet C, Couvreur P (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54: 631-651. (Pubitemid 35247520)
23. Botella P, Abasolo I, Fernandez Y, Muniesa C, Miranda S, et al. (2011) Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation. J Control Release 156: 246-257.
24. Soma D, Kitayama J, Konno T, Ishihara K, Yamada J, et al. (2009) Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer. Cancer Sci 100: 1979-1985.
25. Emoto S, Yamaguchi H, Kishikawa J, Yamashita H, Ishigami H (2012) Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination. Cancer Sci 103: 1304-1310.
26. Cai J, Guan H, Fang L, Yang Y, Zhu X, et al. (2013) MicroRNA-374a activates Wnt/beta-catenin signaling to promote breast cancer metastasis. J Clin Invest 123: 566-579.